{
  "nctId": "NCT04588077",
  "briefTitle": "Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis",
  "officialTitle": "Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.",
  "protocolDocument": {
    "nctId": "NCT04588077",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-09-11",
    "uploadDate": "2020-10-07T01:07",
    "size": 44530,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04588077/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 200,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2020-09-14",
    "completionDate": "2028-12-01",
    "primaryCompletionDate": "2028-12-01",
    "firstSubmitDate": "2020-09-18",
    "firstPostDate": "2020-10-19"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n\\- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \\< 10 mIU/ml) will be recruited.\n\nExclusion Criteria:\n\n* Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.\n* Those who had previous exposure to hepatitis B.\n* Post liver transplant patients.\n* Less than 18 years old.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "The rates of seroconversion after two doses of Heplisav-B given at 0 and 4 weeks versus three doses of Heplisav-B given at 0, 4 weeks, and 8 weeks.",
        "description": "The rates of seroconversion is defined as an HBsAg antibody concentration â‰¥ 10 mIU/ml.",
        "timeFrame": "12 weeks after completing Heplisav-B series with two doses or three doses"
      }
    ],
    "secondary": [
      {
        "measure": "Factors are associated with a lower likelihood of achieving immunogenicity, such as age, race, MELD scores, etiologies of cirrhosis, comorbidity, immunosuppressive drugs. Those information will be measured or described descriptively by chart review.",
        "description": "Age (years) Race (White, Black, Other). MELD (Model For End-Stage Liver Disease) score: 6-40\n\nEtiologies of cirrhosis will include:\n\nNonalcoholic Fatty Liver Disease (Yes/No). Hepatitis C (Yes/No). Alcohol induced Liver Disease (Yes/No). Autoimmune Hepatitis (Yes/No). Primary Biliary Cholangitis (Yes/No). Primary Sclerosing Cholangitis (Yes/No).\n\nComorbidity will include:\n\nChronic obstructive pulmonary disease (Yes/No). Diabetes mellitus (Yes/No). Hypertension (Yes/No). Coronary artery disease (Yes/No). Acute renal injury (Yes/No). Chronic renal disease (Yes/No). Obesity (Yes/No). The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared. A BMI of 30 and higher is considered obese. Immunosuppressive drugs (Yes/No).",
        "timeFrame": "Through study completion, an average of 1 year"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:25.348Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}